Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Corynebacterium diphtheriae

From Wikipedia, the free encyclopedia
Species of prokaryote

Corynebacterium diphtheriae
Scientific classificationEdit this classification
Domain:Bacteria
Kingdom:Bacillati
Phylum:Actinomycetota
Class:Actinomycetes
Order:Mycobacteriales
Family:Corynebacteriaceae
Genus:Corynebacterium
Species:
C. diphtheriae
Binomial name
Corynebacterium diphtheriae
(Kruse 1886) Lehmann and Neumann 1896 (Approved Lists 1980)[1]

Corynebacterium diphtheriae[a] is a Gram-positivepathogenic bacterium that causesdiphtheria.[2] It is also known as theKlebs–Löffler bacillus because it was discovered in 1884 by GermanbacteriologistsEdwin Klebs (1834–1913) andFriedrich Löffler (1852–1915).[3] While nontoxigenicC. diphtheriae may rarely produce systemic disease by invading tissues,[4] virulence is enhanced when the bacteria are infected by abacteriophage carrying agene which gives rise to atoxin.[5] This toxin causes the disease.[6]

Diphtheria is caused by the adhesion and infiltration of the bacteria into the mucosal layers of the body, primarily affecting the respiratory tract and causing the subsequent release of anexotoxin.[7] The toxin has a localized effect on skin lesions, as well as a metastatic, proteolytic effects on other organ systems in severe infections.[7] Originally a major cause ofchildhood mortality, respiratory diphtheria has become rare in the United States by the vigorous administration ofdiphtheria vaccines starting in 1914.[8][9]

Theincidence of diphtheria has decreased since the development of atoxoid vaccine in 1923.[10] Although diphtheria outbreaks continue to occur, this is often in developing countries where the majority of the population is not vaccinated.[11][12] Cutaneous diphtheria, skin lesions infected by toxigenicC. diphtheriae,[4] are prevalent intropical climates and may contribute to diphtheria outbreaks.[13]: 10 

Classification

[edit]

Four subspecies are recognized:C. d. mitis,C. d. intermedius,C. d. gravis, andC. d. belfanti. The four subspecies differ slightly in theircolonial morphology and biochemical properties, such as the ability to metabolize certain nutrients. All may be either toxigenic (and therefore cause diphtheria) or not toxigenic.

Strain subtyping involves comparing species of bacteria and categorizing them into subspecies.[14] Strain subtyping also helps with identifying the origin of a certain bacteria's outbreak. However, when it comes to the subtyping ofC. diphtheriae, there is not a lot of useful or accurate classification due to the lack of publicly available resources to identify strains and therefore find the origin of outbreaks.[15]

Corynebacterium diphtheriae is part of theC. diphtheriae species complex, which also includesC. belfantii,C. pseudotuberculosis,C. rouxii,C. silvaticum,C. ulcerans[16] andC. ramonii.[17]

Toxin

[edit]
Main article:Diphtheria toxin

C. diphtheriae produces thediphtheria toxin which alters protein function in the host by inactivating theelongation factor EF-2. This causes pharyngitis and 'pseudomembrane' in the throat. The strains that are toxigenic are ones which have been infected with abacteriophage.[18][19]

The diphtheria toxin gene is encoded by acorynephage found in toxigenic strains, integrated into the bacterial chromosome in thelysogenic phase of the bacteriophage.[20]

The diphtheria toxin repressor is mainly controlled by iron. It serves as the essential cofactor for the activation of target DNA binding. A low concentration of iron is required in the medium for toxin production. At high iron concentrations, iron molecules bind to anaporepressor on the beta bacteriophage, which carries theTox gene. When bound to iron, the aporepressor shuts down toxin production.[21]Elek's test for toxigenicity is used to determine whether the organism is able to produce the diphtheria toxin.[22]

Diphtheria toxin can also be produced by certain strains ofCorynebacterium ulcerans andCorynebacterium pseudotuberculosis, which arezoonotic pathogens,[13]: 6  as well as other phage-infected members of theC. diphtheriae complex.[16][17]

Identification

[edit]

To identifyC. diphtheriae, aGram stain is performed to showGram-positive, highlypleomorphic organisms often looking like Chinese letters. Stains such asAlbert's stain andPonder's stain are used to demonstrate themetachromaticgranules formed in the polar regions. The granules are called polar granules, orvolutin granules, known under the eponymous name Babes-Ernst granules after their inventorsPaul Ernst andVictor Babes. An enrichment medium, such asLöffler's medium, preferentially growsC. diphtheriae. After that, a differential plate known astellurite agar, allows allCorynebacteria (includingC. diphtheriae) to reduce tellurite to metallic tellurium. The tellurite reduction is colourimetrically indicated by brown colonies for mostCorynebacterium species or by a black halo around theC. diphtheriae colonies. The organism producescatalase but noturease, which differentiates it fromCorynebacterium ulcerans.C. diphtheriae does not producepyrazinamidase which differentiates fromCorynebacterium striatum andCorynebacterium jeikeium.[23]

Pathogenicity

[edit]
Main article:Diphtheria
An adherent, dense, grey pseudomembrane covering the tonsils is classically seen in diphtheria.

Corynebacterium diphtheriae is the bacterium that causes the disease called diphtheria. Bacteriophages introduce a gene into the bacterial cells that makes a strain toxigenic. The strains that are not infected with these viruses are harmless.[6]C. diphtheriae is a rod-shaped, Gram-positive, non spore-forming, and nonmotile bacterium.[24]C. diphtheriae has shown to exclusively infect humans. It is believed that humans may be the reservoir for this pathogen. However, there have been extremely rare cases in whichC. diphtheriae has been found in animals. These infections were only toxigenic in two dogs and two horses.[25]

The disease occurs primarily in tropical regions anddeveloping countries. Immunocompromised individuals, poorly immunized adults, and unvaccinated children are at the greatest risk of contracting diphtheria. Mode of transmission is person-to-person contact via respiratory droplets (i.e., coughing or sneezing). Less commonly, it could also be passed by touching open sores or contaminated surfaces. During the typical course of disease, the body region most commonly affected is the upper respiratory system. A thick, grey coating accumulates in the nasopharyngeal region, making breathing and swallowing more difficult. The disease remains contagious for at least two weeks following the disappearance of symptoms but has been known to last for up to a month.[26]

The most common routes of entry forC. diphtheriae are the nose, tonsils, and throat. Individuals suffering from the disease may experience sore throat, weakness, fever, and swollen glands. This could cause even more dangerous symptoms such as shortness of breath.[27] If left untreated, diphtheria toxin may enter the bloodstream, causing damage to the kidneys, nerves, and heart. Extremely rare complications include suffocation and partial paralysis. A vaccine,DTaP, effectively prevents the disease and is mandatory in the United States for participation in public education and some professions (exceptions apply).[7]

The first step ofC. diphtheriae infection involves the toxigenic bacteria colonizing a mucosal layer. In young children, this typically occurs in the upper respiratory tract mucosa. In adults, the infection is limited mostly to the tonsillar region. Some unusual sites of infection include the heart, larynx, trachea, bronchi, and anterior areas of the mouth including the buccal mucosa, the lips, tongue, and the hard and soft palate.[28] The bacteria have several virulence factors to help them localize on areas of the respiratory tract, many of which are yet to be fully understood as diphtheria does not affect many model hosts such as mice. One common virulence factor that has been studiedin vitro is DIP0733, a multi-functional protein that has been shown to have a role in bacterial adhesion to host cells and fibrogen-binding qualities. In experiments with mutant strains of theC. diphtheriae, adhesion and epithelial infiltration decreased significantly. The ability to bind to extracellular matrices aids the bacteria in avoiding detection by the body's immune system.[29]

The diphtheritic lesion is often covered by a pseudomembrane composed of fibrin, bacterial cells, and inflammatory cells. Diphtheria toxin can be proteolytically cleaved into two fragments: an N-terminal fragment A (catalytic domain), and fragment B (transmembrane and receptor binding domain). Fragment A catalyzes the NAD+ -dependent ADP-ribosylation of elongation factor 2, thereby inhibiting protein synthesis in eukaryotic cells. Fragment B binds to the cell surface receptor and facilitates the delivery of fragment A to the cytosol.[28]

Once the bacteria have localized in one area, they start multiplying and create the inflammatory pseudomembrane. Individuals with faucial diphtheria typically have the pseudomembrane grow over the tonsil and accessory structures, uvula, soft palate, and possibly the nasopharyngeal area. In upper respiratory tract diphtheria, the pseudomembrane can grow on the pharynx, larynx, trachea, and bronchi/bronchioles. The pseudomembrane starts off white in colour and then later becomes dirty-grey and tough due to the necrotic epithelium.[28]

Pseudomembrane formation on the trachea or bronchi will decrease the efficiency of airflow. Over time, the diffusion rate in the alveoli decreases due to the lower airflow and decreases the partial pressure of oxygen in the systemic circulation, which can causecyanosis and suffocation.[28]

Transmission

[edit]

Mode of transmission is person-to-person contact via respiratory droplets (i.e., coughing or sneezing), and less commonly, by touching open sores or contaminated surfaces.[15]

Vaccine

[edit]

A vaccine,DTaP, effectively prevents the disease and is mandatory in the United States for participation in public education and some professions (exceptions apply).

The invention of the toxoid vaccine, which provides protection againstCorynebacterium diphtheriae, caused a dramatic shift in the bacterium's rate of infection in the United States. Even though the vaccine was first made in the early 1800s, it did not become widely available until the early 1910s. According to the National Health and Nutrition Examination Survey (NHANES), "80 per cent of persons age 12 to 19 years were immune to diphtheria" due to the wide use of the vaccine in the United States.[30]

Diagnosis

[edit]
Main article:Diphtheria

Diagnosis of respiratoryC. diphtheriae is made based on presentation clinically, whereas non-respiratory diphtheria may not be clinically suspected therefore laboratory testing is more reliant. Culturing is the most accurate kind of testing that will confirm or deny the prevalence of diphtheria toxins. The testing is done by swabbing the possibly infected area, as well as any lesions and sores.[31]

Treatment and prevention

[edit]
Main article:Diphtheria

When a toxigenic strain ofCorynebacterium diphtheriae infects the human body, it releases harmful toxins, especially to the throat.Antitoxins are used to prevent further harm. Antibiotics are also used to fight the infection. Typical antibiotics that are used against diphtheria involve penicillin or erythromycin. People infected with diphtheria must quarantine for at least 48 hours after being prescribed antibiotics. To confirm that the person is no longer contagious, tests are performed ensure that the bacteria have been cleared. People are then vaccinated to prevent further transmission of the disease.[32]

The wide use of the diphtheria vaccine dramatically decreased the rate of infection and allows for primary prevention of the disease. Most people receive a 3-in-1 vaccine that consists of protection against diphtheria, tetanus and pertussis, which is commonly known as the DTaP or Tdap vaccine. DTaP vaccine is for children while the Tdap vaccine is known for adolescents and adults.[11]

In the United States, the DTaP vaccine to parents of infants which typically involves a series of five shots is recommended. These vaccines are injected through the arm or thigh and are administered when the infant is 2 months, 4 months, 6 months, 15–18 months and then 4–6 years old.[11]

Possible side events that are associated with the diphtheria vaccine include "mild fever, fussiness, drowsiness or tenderness at the injection site". Although it is rare, the DTaP vaccine may cause an allergic reaction that causes hives or a rash to breakout within minutes of administering the vaccine.[11]

Genetics

[edit]

The genome ofC. diphtheriae consists of a single circular chromosome of 2.5 Mbp, with noplasmids.[33] Its genome shows an extremecompositional bias, being noticeably higher in G+C near the origin than at the terminus.[27]

TheCorynebacterium diphtheriae genome is a single circular chromosome that has no plasmids. These chromosomes have a high G+C content which is what contributes to their high genetic diversity. The high content of guanine and cytosine is not constant across the entire genome of the bacteria. There is a terminus of replication around the ~740kb region that causes a decrease in the G+C content. In other bacteria, it is often seen that the G+C content gets smaller near the terminus, butC. diphtheriae is a considerably strong genome that has this occurrence. Chromosomal replication is one of the ways this happens within this genome.[27]

Notes

[edit]
  1. ^Pronunciation:/kɔːˈrnəbæktɪəriəmdɪfˈθɪərii,-rɪnə-/.

References

[edit]
  1. ^Parte AC."Corynebacterium".LPSN.
  2. ^Hoskisson PA (June 2018)."Microbe Profile: Corynebacterium diphtheriae – an old foe always ready to seize opportunity".Microbiology.164 (6):865–867.doi:10.1099/mic.0.000627.PMC 6097034.PMID 29465341.
  3. ^Barksdale L (December 1970)."Corynebacterium diphtheriae and its relatives".Bacteriological Reviews.34 (4):378–422.doi:10.1128/br.34.4.378-422.1970.PMC 378364.PMID 4322195.
  4. ^abMahesh M, Le T (2025)."Cutaneous Diphtheria—A Potential Lurking Public Health Crisis".Annals of Internal Medicine: Clinical Cases.4 (9).doi:10.7326/aimcc.2025.0549.S2CID 281365405.
  5. ^Ott L, Möller J, Burkovski A (March 2022)."Interactions between the Re-Emerging PathogenCorynebacterium diphtheriae and Host Cells".International Journal of Molecular Sciences.23 (6): 3298.doi:10.3390/ijms23063298.PMC 8952647.PMID 35328715.
  6. ^abMuthuirulandi Sethuvel DP, Subramanian N, Pragasam AK, Inbanathan FY, Gupta P, Johnson J, et al. (2019)."Insights to the diphtheria toxin encoding prophages amongst clinical isolates ofCorynebacterium diphtheriae from India".Indian Journal of Medical Microbiology.37 (3):423–425.doi:10.4103/ijmm.IJMM_19_469.PMID 32003344.
  7. ^abcHadfield TL, McEvoy P, Polotsky Y, Tzinserling VA, Yakovlev AA (February 2000)."The pathology of diphtheria".The Journal of Infectious Diseases.181 (Suppl 1):S116–S120.doi:10.1086/315551.PMID 10657202.
  8. ^National Museum of American History."The Antibody Initiative: Diphtheria Treatments and Prevention".Smithsonian. Retrieved17 January 2026.
  9. ^Tiwari TS, Wharton M (2018). "19 - Diphtheria Toxoid". In Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds.).Plotkin's Vaccines (Seventh ed.). Elsevier. pp. 261–275.doi:10.1016/B978-0-323-35761-6.00019-5.ISBN 978-0-323-35761-6.
  10. ^"Diphtheria: A Hundred Years Ago, the First Toxoid Vaccine".The Research Journal. Institut Pasteur. 10 December 2023. Retrieved17 January 2026.
  11. ^abcd"Diphtheria – Symptoms and causes".Mayo Clinic. Retrieved2022-11-17.
  12. ^Clarke KE, MacNeil A, Hadler S, Scott C, Tiwari TS, Cherian T (October 2019)."Global Epidemiology of Diphtheria, 2000-2017".Emerging Infectious Diseases.25 (10):1834–1842.doi:10.3201/eid2510.190271.PMC 6759252.PMID 31538559.
  13. ^abPublic health control and management of diphtheria in England: 2025 guidelines(PDF) (Report). UK Health Security Agency. July 2025. Retrieved17 January 2026.
  14. ^Shariat N, Dudley EG (January 2014)."CRISPRs: molecular signatures used for pathogen subtyping".Applied and Environmental Microbiology.80 (2):430–439.Bibcode:2014ApEnM..80..430S.doi:10.1128/AEM.02790-13.PMC 3911090.PMID 24162568.
  15. ^abSangal V, Hoskisson PA (September 2016)."Evolution, epidemiology and diversity of Corynebacterium diphtheriae: New perspectives on an old foe"(PDF).Infection, Genetics and Evolution.43:364–70.Bibcode:2016InfGE..43..364S.doi:10.1016/j.meegid.2016.06.024.PMID 27291708.
  16. ^abPrates FD, Araújo MR, Sousa EG, Ramos JN, Canário Viana MV, de Castro Soares S, Sanches dos Santos L, de Carvalho Azevedo VA (2024). Britz ML (ed.)."First Pangenome ofCorynebacterium rouxii, a Potentially Toxigenic Species ofCorynebacterium diphtheriae Complex".Bacteria.3 (2):99–117.doi:10.3390/bacteria3020007.
  17. ^abCrestani C, Arcari G, Landier A, Passet V, Garnier D, Brémont S, Armatys N, Carmi-Leroy A, Toubiana J, Badell E, Brisse S (2023)."Corynebacterium ramonii sp. nov., a novel toxigenic member of theCorynebacterium diphtheriae species complex".Research in Microbiology.174 (7) 104113.doi:10.1016/j.resmic.2023.104113.PMID 37572824.
  18. ^Freeman VJ (June 1951)."Studies on the virulence of bacteriophage-infected strains of Corynebacterium diphtheriae".Journal of Bacteriology.61 (6):675–688.doi:10.1128/JB.61.6.675-688.1951.PMC 386063.PMID 14850426.
  19. ^Freeman VJ, Morse IU (March 1952)."Further observations on the change to virulence of bacteriophage-infected a virulent strains of Corynebacterium diphtheria".Journal of Bacteriology.63 (3):407–414.doi:10.1128/JB.63.3.407-414.1952.PMC 169283.PMID 14927573.
  20. ^Mokrousov I (January 2009). "Corynebacterium diphtheriae: genome diversity, population structure and genotyping perspectives".Infection, Genetics and Evolution.9 (1):1–15.Bibcode:2009InfGE...9....1M.doi:10.1016/j.meegid.2008.09.011.PMID 19007916.
  21. ^Nester EW, Anderson DG, Roberts CE, Pearsall NN, Nester MT (2004).Microbiology: A Human Perspective (Fourth ed.). Boston: McGraw-Hill Education.ISBN 978-0-07-291924-0.
  22. ^Breton D (December 1994). "[Non-toxic Corynebacterium diphtheriae septicemia with endocarditis in an earlier healthy adult. First case and review of the literature]".Presse Médicale (in French).23 (40):1859–1861.PMID 7899317.
  23. ^"UK Standards for Microbiology Investigations – Identification of Corynebacterium species"(PDF). 12 December 2023.
  24. ^"Diphtheria Infection | Home | CDC".www.cdc.gov. 2017-04-10. Retrieved2017-11-27.
  25. ^Tyler R, Rincon L, Weigand MR, Xiaoli L, Acosta AM, Kurien D, et al. (August 2022)."Toxigenic Corynebacterium diphtheriae Infection in Cat, Texas, USA".Emerging Infectious Diseases.28 (8):1686–1688.doi:10.3201/eid2808.220018.PMC 9328917.PMID 35876749.
  26. ^"Diphtheria".MedlinePlus. U.S. National Library of Medicine. Retrieved2017-11-27.
  27. ^abcCerdeño-Tárraga, A. M.; Efstratiou, A.; Dover, L. G.; Holden, M. T. G.; Pallen, M.; Bentley, S. D.; Besra, G. S.; Churcher, C.; James, K. D.; De Zoysa, A.; Chillingworth, T.; Cronin, A.; Dowd, L.; Feltwell, T.; Hamlin, N. (2003-11-15)."The complete genome sequence and analysis of Corynebacterium diphtheriae NCTC13129".Nucleic Acids Research.31 (22):6516–6523.doi:10.1093/nar/gkg874.ISSN 0305-1048.PMC 275568.PMID 14602910.
  28. ^abcdSharma NC, Efstratiou A, Mokrousov I, Mutreja A, Das B, Ramamurthy T (December 2019)."Diphtheria".Nature Reviews. Disease Primers.5 (1): 81.doi:10.1038/s41572-019-0131-y.PMID 31804499.S2CID 208737335.
  29. ^Antunes CA, Sanches dos Santos L, Hacker E, Köhler S, Bösl K, Ott L, et al. (March 2015)."Characterization of DIP0733, a multi-functional virulence factor of Corynebacterium diphtheriae".Microbiology.161 (Pt 3):639–647.doi:10.1099/mic.0.000020.PMID 25635272.
  30. ^Stratton K, Ford A, Rusch E, Clayton EW, et al. (Committee to Review Adverse Effects of Medicine) (2011-08-25).Diphtheria Toxoid–, Tetanus Toxoid–, and Acellular Pertussis–Containing Vaccines. National Academies Press (US).
  31. ^"Diagnosis, Treatment, and Complications | CDC".www.cdc.gov. 2022-09-09. Retrieved2022-11-18.
  32. ^"Diphtheria: Causes, Symptoms, Treatment & Prevention".Cleveland Clinic. Retrieved2022-10-26.
  33. ^Cerdeño-Tárraga AM, Efstratiou A, Dover LG, Holden MT, Pallen M, Bentley SD, et al. (November 2003)."The complete genome sequence and analysis of Corynebacterium diphtheriae NCTC13129".Nucleic Acids Research.31 (22):6516–6523.doi:10.1093/nar/gkg874.PMC 275568.PMID 14602910.

See also

[edit]

External links

[edit]
Actinomycineae
Actinomycetaceae
Propionibacteriaceae
Corynebacterineae
Mycobacteriaceae
M. tuberculosis/
M. bovis
M. leprae
Nontuberculous
R1:
R2:
R3:
R4/RG:
Nocardiaceae
Corynebacteriaceae
Bifidobacteriaceae
Portal:
Corynebacterium diphtheriae
National
Other
Retrieved from "https://en.wikipedia.org/w/index.php?title=Corynebacterium_diphtheriae&oldid=1333442504"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp